Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04386005 · ClinicalTrials.gov registry record · NA

Continuous Glucose Monitoring in At-Risk Newborns

A NA study of Neonatal Hypoglycemia, sponsored by Milton S. Hershey Medical Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT04386005: Recruiting NA study of Neonatal Hypoglycemia, sponsored by Milton S. Hershey Medical Center.

NCT04386005 is a NA study of Neonatal Hypoglycemia that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 100 participants, below the 122-participant average among 5 other Neonatal Hypoglycemia trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04386005, a NA study of Neonatal Hypoglycemia, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Hypoglycemia (low blood glucose) is a very common problem in newborns, and has been associated with poor neurodevelopment, cognition, and school performance. At-risk newborns (infants of diabetic mothers \[IDM\], large \[LGA\] and small \[SGA\] for gestational age infants, and late preterm \[LPT\] infants) undergo a hypoglycemia screening protocol that involves numerous intermittent needle sticks to test glucose levels on bedside glucometers; however, continuous glucose monitoring (CGM, currently not approved for clinical use in babies), via a small sensor placed in the thigh (only 1 needle stick), would likely decrease pain while providing continuous glucose levels. This study will evaluate the feasibility, safety, and precision of CGM in at-risk newborns, and determine if this method would decrease the amount of painful procedures and episodes of hypoglycemia missed by intermittent sampling. As part of regular medical care, participants will undergo intermittent blood glucose screening with heel sticks as per the current hospital standard of care protocol. Regular medical care involves checking the participant's blood glucose via heel stick every few hours using a bedside glucometer, with another heel stick to confirm low values in the laboratory. If the participant has low values, he/she may be treated with oral glucose gel, feedings of breast milk or formula, or intravenous (IV) fluids in the Neonatal Intensive Care Unit (NICU). This research study involves placing a CGM device in addition to undergoing the current blood glucose screening protocol and treatment. As soon as possible after birth, a continuous glucose monitoring device (Dexcom G7) will be placed on the participant's thigh by a research team member, and will blindly continuously record glucose levels that will be analyzed after discharge. Everyone who agrees to participate in this study will have placement of this experimental device. The investigational device will stay in place for the same amo

Primary Outcome

Bland-Altman analysis to evaluate bias and the agreement interval between CGM and intermittent testing

Conditions Studied

Interventions

  • DEVICE Continuous Glucose Monitoring Device

Study Locations (1)

Pennsylvania

  • Penn State Health Milton S Hershey Medical Center - Hershey

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-08-09
Est. Completion 2026-06
Phase NA
Milton S. Hershey Medical Center

396 total trials

What NCT04386005 shows while recruiting

NCT04386005 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 122-participant average among 5 other Neonatal Hypoglycemia trials with a reported enrollment target (18% lower).

The record links to 1 condition, with Neonatal Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which Continuous Glucose Monitoring Device is the first listed.

NCT04386005 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04386005 about?

NCT04386005 is a clinical study titled "Continuous Glucose Monitoring in At-Risk Newborns". Hypoglycemia (low blood glucose) is a very common problem in newborns, and has been associated with poor neurodevelopment, cognition, and school performance. At-risk newborns (infants of diabetic mothers \[IDM\], large \[LGA\] and small \[SGA\] for gestational age infants, and late preterm \[LPT\] i...

What is the current status of trial NCT04386005?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2021-08-09. Estimated completion is 2026-06.

What conditions does trial NCT04386005 study?

This clinical trial studies the following conditions: Neonatal Hypoglycemia.

What interventions are being tested in trial NCT04386005?

The interventions under investigation include: Continuous Glucose Monitoring Device (DEVICE).

Who is sponsoring clinical trial NCT04386005?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04386005 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neonatal Hypoglycemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04386005, the US trial registry maintained by the National Library of Medicine. NCT04386005 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.